Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80
Document › Details

Pronota N.V.. (2/22/11). "Press Release: Pronota and Molecuence Announce Collaboration in Protein Biomarker Discovery". Ghent.

Organisations Organisation Pronota N.V.
  Today MyCartis, Zwijnaarde
  Group MyCartis
  Organisation 2 Molecuence Corporation
  Group Mitsubishi Chemical (Group)
Product Product biomarker discovery services
Index term Index term Mitsubishi Chemical–Pronota: protein biomarker, 201102– collab €na discovery marker for stroke using MASStermind + MASSterclass for Molecuence Corp
Person Person McCooke, Nick (DNA Electronics 201406– CBO beforeOxford Cancer Biomarkers + Pronota + Solexa)

Pronota NV today announced that it has entered into an agreement with Molecuence Corporation, a wholly owned subsidiary of Mitsubishi Chemical Corporation, to discover and validate protein biomarkers in stroke. Pronota will apply its proven proprietary platforms for protein biomarker discovery (MASStermind®) and biomarker verification MASSterclass™) to this project. The financial terms have not been disclosed.

"We're finding potential collaborators are increasingly persuaded by our track record of not only being able to identify novel protein biomarkers, but also of taking these successfully through the verification process to show they are true, robust and clinically relevant discoveries. We're delighted to be working with Molecuence, who are one of the leaders in the field of protein biomarker development for diagnostic applications", commented Nick McCooke, CEO of Pronota.

About Pronota

Pronota was founded in late 2004 to develop protein biomarker diagnostics derived from its proprietary platform that uniquely mines for low-abundance protein biomarkers in blood and other tissues. In this short time, it has successfully implemented its technology and made substantial progress in creating a diagnostic product development pipeline.

Its MASStermind® protein biomarker discovery platform has demonstrated, across many projects, its unerring ability to discover clinically relevant and novel protein biomarkers. Its MASSterclass™ verification platform provides it with a way of verifying within a matter of weeks the prolific output from MASStermind without having to resort to the use of antibody based assays.

About Molecuence

Molecuence Corporation is a wholly owned subsidiary of Mitsubishi Chemical Corporation. The company is principally involved in the development of disease related biomarkers that can enable diagnosis and prediction of accurate disease status. Currently, the company is involved in research and development of advanced biomarkers for cardiovascular and metabolic diseases. Molecuence works in partnership with Kyushu university faculty of medicine and Hisayama research institute for lifestyle diseases. The company is headquartered in Yokohama, Japan.

Contact Pronota:

* Nick McCooke, CEO
* Pronota NV
* Technologiepark 4
* VIB Bio-Incubator
* B-9052 Zwijnaarde / Ghent
* Belgium
* Tel: +32 (0)9 241 11 64
* Fax: +32 (0)9 241 11 69


Record changed: 2019-06-09


Picture EBD Group Digital Medicine & Medtech Showcase 2021 at BTS2021 651x81

More documents for MyCartis

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture [iito] Fighting Customers 650x80px

» top